Identification of Alternative Transcripts Encoding the Essential Murine Gammaherpesvirus Lytic Transactivator RTA

Brian S. Wakeman  
*Emory University School of Medicine*

L. Steven Johnson  
*Washington University School of Medicine in St. Louis*

Clinton R. Paden  
*Emory University School of Medicine*

Kathleen S. Gray  
*Emory University School of Medicine*

Herbert W. Virgin  
*Washington University School of Medicine in St. Louis*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

*Please let us know how this document benefits you.*

**Recommended Citation**

[https://digitalcommons.wustl.edu/open_access_pubs/2854](https://digitalcommons.wustl.edu/open_access_pubs/2854)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Brian S. Wakeman, L. Steven Johnson, Clinton R. Paden, Kathleen S. Gray, Herbert W. Virgin, and Samuel H. Speck
Identification of Alternative Transcripts Encoding the Essential Murine Gammaherpesvirus Lytic Transactivator RTA

Brian S. Wakeman, L. Steven Johnson, Clinton R. Paden, Kathleen S. Gray, Herbert W. Virgin and Samuel H. Speck


Updated information and services can be found at: http://jvi.asm.org/content/88/10/5474

These include:

REFERENCES

This article cites 67 articles, 41 of which can be accessed free at: http://jvi.asm.org/content/88/10/5474#ref-list-1

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Identification of Alternative Transcripts Encoding the Essential Murine Gammaherpesvirus Lytic Transactivator RTA

Brian S. Wakeman, L. Steven Johnson, Clinton R. Paden, Kathleen S. Gray, Herbert W. Virgin, Samuel H. Speck

Emory Vaccine Center and Department of Microbiology & Immunology, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

ABSTRACT
The essential immediate early transcriptional activator RTA, encoded by gene 50, is conserved among all characterized gammaherpesviruses. Analyses of a recombinant murine gammaherpesvirus 68 (MHV68) lacking both of the known gene 50 promoters (G50DbKo) revealed that this mutant retained the ability to replicate in the simian kidney epithelial cell line Vero but not in permissive murine fibroblasts following low-multiplicity infection. However, G50DbKo replication in permissive fibroblasts was partially rescued by high-multiplicity infection. In addition, replication of the G50DbKo virus was rescued by growth on mouse embryonic fibroblasts (MEFs) isolated from IFN-α/βR−/− mice, while growth on Vero cells was suppressed by the addition of alpha interferon (IFN-α). 5′ rapid amplification of cDNA ends (RACE) analyses of RNAs prepared from G50DbKo and wild-type MHV68-infected murine macrophages identified three novel gene 50 transcripts initiating from 2 transcription initiation sites located upstream of the currently defined proximal and distal gene 50 promoters. In transient promoter assays, neither of the newly identified gene 50 promoters exhibited sensitivity to IFN-α treatment. Furthermore, in a single-step growth analysis RTA levels were higher at early times postinfection with the G50DbKo mutant than with wild-type virus but ultimately fell below the levels of RTA expressed by wild-type virus at later times in infection. Infection of mice with the MHV68 G50DbKo virus demonstrated that this mutant virus was able to establish latency in the spleen and peritoneal exudate cells (PECs) of C57BL/6 mice with about 1/10 the efficiency of wild-type virus or marker rescue virus. However, despite the ability to establish latency, the G50DbKo virus mutant was severely impaired in its ability to reactivate from either latently infected splenocytes or PECs. Consistent with the ability to rescue replication of the G50DbKo mutant by growth on type I interferon receptor null MEFs, infection of IFN-α/βR−/− mice with the G50DbKo mutant virus demonstrated partial rescue of (i) acute virus replication in the lungs, (ii) establishment of latency, and (iii) reactivation from latency. The identification of additional gene 50/RTA transcripts highlights the complex mechanisms involved in controlling expression of RTA, likely reflecting time-dependent and/or cell-specific roles of different gene 50 promoters in controlling virus replication. Furthermore, the newly identified gene 50 transcripts may also act as negative regulators that modulate RTA expression.

IMPORTANCE
The viral transcription factor RTA, encoded by open reading frame 50 (Orf50), is well conserved among all known gammaherpesviruses and is essential for both virus replication and reactivation from latently infected cells. Previous studies have shown that regulation of gene 50 transcription is complex. The studies reported here describe the presence of additional alternatively initiated, spliced transcripts that encode RTA. Understanding how expression of this essential viral gene product is regulated may identify new strategies for interfering with infection in the setting of gammaherpesvirus-induced diseases.

Herpesviruses are large double-stranded DNA viruses. The hallmark of all herpesvirus infections is their ability to persist for the lifetime of the host, which is marked by sporadic virus reactivation, replication, and shedding. The herpesvirus family is divided into three classes, the alpha-, beta-, and gammaherpesviruses. While both alpha- and betaherpesviruses generally exhibit broad tropism and the ability to infect a range of cell types, gammaherpesviruses are unique in that they are mainly lymphotropic, infecting and establishing latency in T or B lymphocytes. Gammaherpesviruses are also unique in that they are associated with a variety of lymphomas. Kaposi’s sarcoma-associated virus (KSHV) is associated with tumor development in its namesake Kaposi’s sarcoma, as well as multicentric Castleman’s disease and primary effusion lymphoma. Epstein-Barr virus (EBV) is tightly associated with the development of several human malignancies, including nasopharyngeal carcinoma, Hodgkin’s lymphoma, Burkitt’s lymphoma, and posttransplant lymphoproliferative disease (1). Though both KSHV- and EBV-associated malignancies are rare, their prevalence is elevated in people who are immunocompromised via either immunosuppressive therapies or HIV infection (2–4).

While in vitro cell culture systems exist to study the two human gammaherpesviruses EBV and KSHV, these viruses have a narrow host tropism which severely limits in vivo studies. This has generated a need for robust small-animal models to further investigate primary viral infection, establishment of latency, and reactivation in the context of natural infection. Murine gammaherpesvirus 68...
(MHV68) has emerged as the leading animal model for characterizing gammaherpesvirus pathogenesis in vivo. MHV68 is a natural pathogen of wild murid rodents and readily infects laboratory strains of mice (5). Complete sequencing of the MHV68 genome revealed extensive homology to those of both EBV and KSHV (6). MHV68 infects multiple organs, establishes latency in the spleen and lymph nodes, is primarily lymphotropic, and is associated with development of lymphoproliferative disease and lymphomas (7–9).

An area of the MHV68 genome that is well conserved in both sequence homology and function is the gene 50 region, which encodes the essential immediate early viral transcriptional activator RTA (also known as R or BRLF1). Notably, the MHV68, KSHV, and EBV gene 50 transcripts exhibit similar splicing patterns, promoters, and genome locations (Fig. 1). Furthermore, ectopic expression of RTA in cells latently infected with MHV68, herpesvirus saimiri (HVS), KSHV, and EBV is capable of driving virus reactivation (10, 11), mediated through RTA activation of viral lytic cycle-associated gene promoters (12, 13–15). RTA feeds on to distal promoter encodes a 181-bp amplification product was then used as the template for a round two amplification (of which represent extensions of exon 0 and the one a completely unique exon. To further characterize these promoters, we generated an MHV68 mutant lacking both the proximal and distal gene 50 promoters (G50DblKo). We show the G50DblKo virus retains the ability to replicate to levels similar to those for the wild-type (WT) virus, but only in the absence of a type I interferon (IFN) response. Furthermore, we show that the G50DblKo virus is extremely sensitive to type I interferons both in vitro and in vivo. We also show that despite the replication defect observed in the absence of a type I interferon response, the G50DblKo virus established a latent infection in both splenocytes and PECs, although it was unable to reactivate from either splenocytes or PECs. Importantly, the replication and latency defects exhibited by the G50DblKo mutant were largely rescued by infection of mice lacking a type I interferon response. Finally, despite the sensitivity of the G50DblKo mutant virus to type I IFNs, we show that the newly identified promoters themselves are not directly sensitive to IFN-α, indicating that type I IFNs likely act downstream of RTA transcription.

MATERIALS AND METHODS

Generation of G50DblKo and G50DblKo.MR viruses. The MHV68. G50DblKo virus was generated using the galk-mediated Red recombineering method as described previously (17, 18). Briefly, we introduced the MHV68 bacterial artificial chromosome (BAC) into the galk bacterial strain SW102, where the galk was inserted into the Orf50 locus. To generate the Orf50-galk swap, we amplified the galk gene from the plasmid pGalk using the primers GalK-G50-F (5'-CTTAAAGAGGAGGAGTGTTGGCAAGTACCCATCTCATTCATGCACGACTGTCCTCTT-3') and GalK-G50-R (5'-CTTAAAGGAGGAGCTTATGGACTCCAGCTGAAGCTTAGTGTGACTGTCCTCGG-3'). This PCR product generated from pGalk includes 50 bp of homologous sequence upstream and downstream from the Orf50 locus. The PCR product was then introduced into the SW102 cells through electroporation, and those cells expressing recombinants were selected through the use of minimal medium with galactose. The ORF50/GalK recombinant BAC mutants (MHV68.A50galk) were confirmed through analyses using multiple restriction endonucleases.

To generate the G50DblKo virus, two separate PCRs with 25-μl reaction mixtures were performed on MHV68 WT BAC with 30 cycles using Phusion polymerase (New England BioLabs) and the following cycling conditions: 94°C for 30 s, 58°C for 30 s, and 72°C for 1 min. The primers used for reaction one amplification were forward primer Orf50f65040_65089 (5’-CTTAAAGAGGAGGAGCTTATGGACTCCAGCTGAAGTACCCATCTCATTCATGCACGACTGTCCTCTT-3’) and reverse primer Orf50f65040_65089 (5’-CTTAAAGAGGAGGAGCTTATGGACTCCAGCTGAAGTACCCATCTCATTCATGCACGACTGTCCTCTT-3’). The primers used for reaction two amplification were reverse primer Orf50R66641_66690 (5’-CTTAAAGAGGAGGAGCTTATGGACTCCAGCTGAAGTACCCATCTCATTCATGCACGACTGTCCTCTT-3’) and forward primer Orf50f505040_65089 (5’-CTTAAAGAGGAGGAGCTTATGGACTCCAGCTGAAGTACCCATCTCATTCATGCACGACTGTCCTCTT-3’). Generating overlapping PCR products to be used in round two amplification (of note, each internal primer contained a HindIII restriction enzyme site to be used for diagnostic purposes). Two microliters of each round one amplification product was then used as the template for the next round reaction using the external forward primer from reaction one
Orf50F65040_65089 and the reverse external primer from reaction two Orf50R66641_66690. The resulting reaction, containing a 50-bp deletion within the distal promoter region of the Orf50 locus, was gel purified and used as the template for a round two reaction using the same external primers as before, Orf50F65040_65089 and Orf50R66641_66690. The resulting PCR product was gel purified and then used as the template for reaction two amplification were reverse primer Orf50F65040_65089 (5'-CTTAAAGGAGGAGCTGTTGGCAGTGCTTGCTGAAAATACCTCATC-3') with forward primer Orf50PpKORHindIII (5'-AACACCCAGCAGCATGTCCAAACACT-3') with reverse primer Orf50PpKORHindIII (5'-GAAGCATGTTAGATGAAAGCTCAGGAAATTGTATGTGC-3') and the primers used for reaction one amplification were forward primer Orf50F65040_65089 (5'-CTTAAAGGAGGAGCTGTTGGCAGTGCTTGCTGAAAATACCTCATC-3') with reverse primer Orf50PpKORHindIII (5'-AACACCCAGCAGCATGTCCAAACACT-3').

Production of virus. Both the G50BlkO and G50BlkO MR viruses were generated from yellow fluorescent protein (YFP) BAC (19). In order to ensure proper viral growth of the G50BlkO virus, a protocol was developed in which the virus would be passaged and titers determined in the absence of type I interferons. Both mutant and marker rescue BACs were transfected using LT-1 transfection reagent (Mirus) into Vero cells expressing Cre-recombinase (Vero-Cre cells). When cells reached 70% cytopathic effect (CPE), cells and supernatants were collected and freeze-thawed three times. The resulting stock was used to infect new Vero-Cre cells to ensure the excision of the BAC. At 70% CPE, cells and supernatants were once again collected, lysed, and used to infect large quantities of Vero-Cre cells to scale up viral stocks. Viral titers were determined as described below.

Tissue culture. Mouse embryonic fibroblasts (MEFs) and NIH 3T12, Raw264.7, and Vero-Cre cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 2 mM l-glutamine, 100 U of streptomycin per ml, and 100 U of penicillin per ml (cMEM). Vero-Cre cells used for virus generation were passaged with the addition of 300 µg of hygromycin B/ml. Cells were maintained at 37°C in a tissue culture incubator with 5% CO₂. MEFs were obtained from C57Bl/6 mouse embryos, and IFN-α/βR−/− MEFs were obtained from 129Sv/J mice as previously described (20).

Growth curves, plaque assays, and viral titers. Growth curves were performed using Vero-Cre, 3T12, IFN-α/βR−/− MEF, or C57Bl/6 MEF cells plated in six-well plates at a concentration of 1.75 × 10⁵ cells per well 24 h prior to infection. The cellular concentration after 24 h was determined, and viral stocks were diluted to a 200 µl volume in cMEM at multiplicities of infection (MOIs) of 0.01, 0.1, and 10. These inoculums were added to the cellular monolayer, and plates were rocked every 15 min at 37°C for 1 h. After 1 h, fresh cMEM at a volume of 2 ml was added back to each well. The contents of the wells were collected at the indicated time points and frozen at −80°C until plaque assays were performed to determine titers. Growth curves with the addition of mouse recombinant IFN-α (Milenyi Biotec) were performed in a similar manner, but IFN-α was added to the plated cells at a concentration of 10,000 IU/ml 1 h before infection. IFN-α was subsequently added at a concentration of 5,000 IU/ml every 24 h for the duration of the infection. Plaque assays were performed by plating Vero-Cre cells in six-well plates at a concentration of 1.75 × 10⁵ cells per well 24 h prior to infection. Viral stocks or growth curve stocks at the indicated time points were freeze-thawed 3 times, and a 10-fold serial dilution was generated. 200 µl of each dilution was added to the Vero-Cre monolayer, and plates were rocked every 15 min at 37°C for 1 h. After 1 h, cells were overlaid with 2% fetal bovine serum (FBS) complete medium containing 20 µl/liter methylcellulose (Sigma). Plaques were visualized at 14 days postinoculation by staining with neutral red (Sigma) at a concentration of 6% overnight.

RACE analysis. One-hundred-milliliter plates were seeded with Raw264.7, Vero-Cre, or IFN-α/βR−/− MEFs in cMEM and 24 h later were infected with WT-YFP or G50BlkO virus at an MOI of 5. Total RNA was isolated from these cells at 24 or 48 h postinfection using TRIZol reagent (Invitrogen). Five micrograms of RNA was DNase I treated (Invitrogen) and subjected to 5’ rapid amplification of cDNA ends (RACE) performed using the GeneRacer system (Invitrogen). RACE-ready cDNA was generated using Superscript III (Invitrogen) reverse transcription using random primers as per the manufacturer's instructions. RACE-ready cDNA was used to look for additional 5’ transcripts through the use of nested PCR utilizing Phusion high-fidelity Taq (NEB) and Platinum Taq (Invitrogen). Nested PCR was performed using the 5’ universal forward primer (round 1), the 5’ universal forward primer (round 2), and various reverse primers located in the Orf50 region: E2R1 (5’-ATTCTGACAG AACTGCAGGCCAGAGGTTGA-3’), E2R2 (5’-CGAATGGGCTGGGC CAGAAGACG-3’), E1R (5’-TAAATCTCATGTGCACCTT-3’), and E0R (5’-TTTGAAATGTGTCGCTGGTGTG-3’). The following cycling conditions for Phusion Taq were used with 1 µl of cDNA in a 50-µl PCR mixture: 98°C for 30 s; 30 cycles of denaturing at 98°C for 10 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s; and a final extension at 72°C for 7 min. Round 2 nested amplification was performed using 2 µl of round 1 product in a 50-µl reaction mixture using the same cycling conditions. The following cycling conditions for Platinum Taq were used with 1 µl of cDNA in a 50-µl PCR mixture: 95°C for 5 min; 30 cycles of denaturing at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s; and a final extension at 72°C for 7 min. Round 2 nested amplification was performed using 2 µl of round 1 product in a 50-µl reaction mixture using the same PCR conditions. PCR products were visualized through running on a 1% ethidium bromide gel, and excised bands were purified using a GeneClean II kit (MP Bio). Purified PCR products from Phusion PCR were ligated into a pCR-Blunt II TOPO vector (Invitrogen), and purified PCR products from Platinum Taq PCR were ligated into either a pCR-TOPO vector (Invitrogen) or a pGEMT-Easy vector (Promega) and analyzed by DNA sequencing (Macrogen USA).

Cell transfections and luciferase assays. Transfection of Vero-Cre and RAW264.7 cells was done in 6-well plates, where at 1 day prior to transfection, cells were plated at 2 × 10⁶ cells per well in cMEM. Transfection mixtures were prepared using 2.5 µg of reported plasmid and 5 ng of pH-R-LUC Renilla luciferase vector as a transfection control. Transfections were performed using LT-1 transfection reagent (Mirus) according to the manufacturer's instructions. pGL4.13[luc] was used as a positive control, pGL4.10[luc] was used as a negative control, and the green fluorescent protein pMaxGFP was used to determine transfection efficiency. For assay mixtures treated with IFN-α, 5,000 IU/ml was added at 24 h posttransfection, and all cells were collected at 48 h posttransfection and lysed. All dual-luciferase assays were performed using a dual-luciferase kit.
Alternative MHV68 Gene 50 Transcripts

from latency were performed as previously described (20, 21). Briefly, to determine the frequency of viral genomes, splenocytes or PECs were serial diluted in 96-well plates and subjected to protease K digestion. After digestion, cells were used in a two-round nested PCR using primers found in the G50 region. PCR products were resolved on a 2% agarose gel and analyzed. To determine the frequency of infected cells reactivating from latency, splenocytes or PECs were counted and diluted in cMEM. Cells were then plated as serial 2-fold dilutions onto an MEF or IFN-α/β/γ−/− MEF monolayer in 96-well plates. In parallel, mechanically disrupted cells also were plated as a serial 2-fold dilution to detect any preformed infectious virus. At 21 days postplating, each well was assessed for CPE and scored as a percentage. For both limiting-dilution PCR and limiting-dilution reactivation, the Poisson distribution was used to determine frequencies.

Mice, infections, and tissue preparation. Female C57Bl/6 mice (The Jackson Laboratory) and 129S2/SvPas.IFN-α/β/γ−/− mice to 6 to 8 weeks of age were maintained at Emory University. Mice were housed under sterile conditions and maintained in accordance with Emory University School of Medicine (Atlanta, GA), as well as all federal guidelines. C57Bl/6 or 129S2/SvPas.IFN-α/β/γ−/− mice were infected intranasally (i.n.) with 1,000 PFU of WT-YFP, G50DbKo, or G50DbKo.MR virus in 20 μl cMEM following isoflurane anesthesia. 129S2/SvPas.IFN-α/β/γ−/− mice were weighed at the time of infection, and weight was monitored daily; mice were sacrificed if they lost 20% of their original body weight. C57Bl/6 mice were also infected intraperitoneally with 1,000 PFU of WT-YFP, G50DbKo, or G50DbKo.MR virus in 20 μl cMEM. With both routes of infection, C57Bl/6 mice were sacrificed at day 18 postinfection or at 7 days postinfection for lung titers. Surviving 129S2/SvPas.IFN-α/β/γ−/− mice were sacrificed at day 28 postinfection. Mice were sacrificed by isoflurane and cervical dislocation. PECs were collected by peritoneal lavage using 10 ml cMEM, spleens were harvested, and splenocytes were prepared by manual homogenization, while lungs were harvested and prepared by mechanical bead disruption using 1.0-mm silica beads. Splenocytes were treated with Tri-as-monium chloride to eliminate red blood cells. All prepared cells were counted using a Cellometer Auto T4 (Nexcelom) and immediately used for lung titer, reactivation, or genome analysis. Cells not used immediately were stored in cMEM+10% dimethyl sulfoxide at −80°C.

Immunoblotting. Infections were carried out as described above for growth curves. At 24, 48, and 72 h postinfection, cells were harvested, washed with 1× phosphate-buffered saline (PBS), and then resuspended in 40 μl of lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, and 0.1% Triton X-100 supplemented with 1 mM Na3VO4 and an EDTA-free protease inhibitor tablet (Roche). Protein quantifications were carried out using a DC protein assay (Bio-Rad). For all blots, 30 μg of protein was mixed with 6× SDS loading buffer, boiled for 5 min at 100°C, and resolved by SDS-PAGE. SDS-polyacrylamide gels were transferred to a nitrocellulose membrane using a semidry apparatus (Bio-Rad). After transfer, membranes were blocked in 5% milk in Tris-buffered saline (TBS)–TWEEN for 1 h at room temperature. After 1 h, membranes were washed three times with TBS-TWEEN, and the primary antibody rabbit anti-MHV68 RTA (22) diluted 1:1,000 in blocking buffer was added and left overnight with rocking at 4°C. Following overnight incubation, the primary antibody was removed and the membrane washed three times with TBS-TWEEN. The membrane was then incubated with the secondary donkey anti-rabbit antibody (Jackson Immunoresearch) diluted 1:2,000 in blocking buffer for 1 h at room temperature. This was followed by three additional washes with TBS-TWEEN. The blot was then developed using SuperSignal West Pico chemiluminescent substrate (Pierce). Membranes were stripped using Restore PLUS Western blot stripping buffer (Thermo Scientific). Membranes were then subjected to the same protocol using the primary mouse monoclonal β-actin antibody (Sigma) at 1:5,000 and the secondary donkey anti-mouse antibody (Jackson Immunoresearch) at 1:5,000. Membranes were also subjected to the same protocol to blot for v-cyclin, where primary rabbit antibody was used.

Limiting-dilution PCR and limiting-dilution reactivation assays. Limiting-dilution PCR to determine the frequency of viral genomes and a limiting-dilution CPE assay to determine the number of cells reactivating...
monoclonal v-cyclin antibody was used at 1:2,000 overnight and the secondary donkey anti-rabbit antibody (Jackson Immunoresearch) was used at 1:2,000 for 1 h at 4°C.

RESULTS
Characterization of the Orf50 distal promoter activity in vitro. We previously reported the generation and characterization of a gene 50 proximal promoter knockout virus (G50pKo), which led to the identification of an additional promoter upstream of the proximal promoter, now referred to as the distal promoter (16). The additional distal promoter drives the expression of a new exon (E0), and the core promoter region corresponds to the first 250 bp upstream of the E0 transcriptional start site. To further characterize the activity of this newly defined promoter region, we generated serial 50-bp deletions (Δ65672-65722, Δ65722-65772, Δ65772-65822, and Δ65822-65872) in the core 250-bp distal promoter region (Fig. 2). These serial 50-bp deletion fragments were cloned into the pGL4.10[luc] reporter plasmid vector, and the resulting reporter plasmids transfected into RAW 264.7 cells. It was previously reported that the gene 50 distal promoter was most active in RAW 264.7 cells with the addition of lipopolysaccharide (LPS) (16).

Luciferase assays confirmed the previous finding that the 250-bp distal promoter region drives significant gene expression, ~30-fold over that with empty vector in the RAW 264.7 cells with the addition of LPS (Fig. 2). Notably, deletion of the sequences from bp 65672 to 65722 resulted in a substantial increase in promoter activity over that with empty vector (~4.6-fold above that observed with the full-length 250-bp promoter construct), indicating the presence of negative cis elements in this region. Similarly, deletion of the sequences from bp 65822 to 65872 also resulted in a strong enhancement of activity (~40-fold above that observed with the full-length 250-bp promoter construct). This would indicate that both of these regions play an important role in limiting gene 50 transcription. Conversely, deletion of the sequences from bp 65772 to 65822 resulted in nearly complete silencing of distal promoter activity (ca.16-fold below that observed with the full-length 250-bp promoter construct), arguing that essential positive cis elements map to this region. Therefore, we chose to delete the latter region in the context of the viral genome to ablate distal gene 50 promoter activity.

Generation of a recombinant MHV68 lacking both the proximal and distal gene 50 promoters. With the identification of a second promoter driving RTA expression, we set out to generate a gene 50 functionally null virus through the deletion of both the distal and proximal promoters. We targeted the promoter regions because previous attempts to propagate gene 50 null viruses harboring mutations within the coding sequence were confounded by the generation of wild-type revertant viruses upon growth on complementing cell lines (i.e., recombination of wild-type gene 50 sequences into the viral genome) (23). Since the gene 50 null mutants grow slowly on complementing cell lines, any wild-type revertant virus quickly overtakes growth of the gene 50 null virus and ends up dominating the viral stock generated. In a previous attempt to overcome this problem, we deleted a 183-bp region of the proximal gene 50 promoter (the only known gene 50 promoter at the time), and it was the analysis of this mutant virus that led to the identification of the distal gene 50 promoter (16). Notably, the deletion introduced into the viral genome to generate the proximal promoter mutant virus (G50pKo) also deleted the splice acceptor site utilized by the distal gene 50 promoter-driven gene 50 transcript. To circumvent this issue, we redesigned the proximal promoter deletion to introduce a 70-bp deletion (corresponding to the region immediately upstream of the exon 1 transcript at coordinates bp 66412 to 66482), leaving the splice acceptor site intact (Fig. 3A). This new gene 50 proximal promoter knockout virus (G50PpKo) was used as the backbone for the generation of the G50DblKo virus.

To disrupt the distal gene 50 promoter, we targeted the 50-bp region from bp 65772 to 65822, which was determined to be essential for promoter activity in the in vitro analyses carried out in the RAW 264.7 cell line (Fig. 2). To confirm the generation of the G50DblKo virus, we sequenced the areas of interest to ensure that the desired deletions were present in the viral genome (data not shown). To further confirm that the virus was intact and that the deletions were inserted into the gene 50 locus, as well as the absence of spontaneous rearrangements and insertions in the viral genome, we digested the mutant BAC with the restriction endonucleases HindIII, PstI, and EcoRI. Notably, in the process of generating the desired deletions, we introduced diagnostic HindIII sites (Fig. 3B and C). HindIII digestion of the G50DblKo mutant yielded the three expected digestion fragments (590 bp, 874 bp, and 1,059 bp), while HindIII digestion of wild-type virus and the marker rescue BAC DNAs resulted in the expected 2,643-bp product. To further assess the presence of the deletions in the gene 50 locus, we performed Southern blotting of the HindIII-digested BAC DNAs (Fig. 3C). We probed the blot with a 1,651-bp probe corresponding to genome coordinates from bp 65040 to 66690, which hybridized to all three fragments generated. Notably, the band intensities varied and were dependent on the extent that the probe overlapped with the fragments generated. Importantly, the wild-type-sized fragment was absent from the G50DblKo and G50PpKo viral genomes, eliminating the possibility of a genome duplication of the gene 50 locus or recombination of the targeting sequences into another region of the viral genome. The final confirmation that the mutant generated was specific to the area of interest was...
the generation and confirmation of the G50DblKo.MR and G50PpKo.MR viruses, in which the Orf50 galK region was replaced with the WT Orf50 region. These marker rescue viruses were all analyzed by sequencing, restriction enzyme digestion, and Southern blotting, and all three methods confirmed reversion back to WT virus. To ensure that the phenotypes observed with the G50pDblKo virus were in fact the result of the desired mutations, this process was conducted four independent times, resulting in the isolation of four independently generated mutant clones. These clones were used throughout the experiments interchangeably, and each experiment was conducted using at least two if not all of the clones. The use of multiple independent clones, in conjunction with the G50pDblKo.MR virus, makes it very unlikely that the observed phenotypes were the result of spontaneous mutations arising elsewhere within the genome.

Replication of the MHV68 G50DblKo mutant, but not wild-type MHV68, is inhibited by type I interferons. To generate the G50DblKo virus, the mutated BAC was first transfected into Vero cells expressing Cre recombinase (Vero-Cre cells) (24) to excise the BAC from the MHV68 BAC. The removal of the BAC sequence is necessary since virus containing BAC sequences is significantly attenuated in vivo (25). Upon successful removal of the BAC in Vero-Cre cells, viral stocks are generated by growth on murine NIH 3T12 cells (24). Surprisingly, Vero-Cre cells transfected with the G50DblKo BAC DNA supported growth of this mutant, indicating that the proximal and distal gene 50 promoters are not required for RTA expression. However, upon low-MOI infection of NIH 3T12 fibroblasts with the resulting viral stock generated from growth in Vero-Cre cells, we failed to observe any replication of the G50DblKo virus. To further investigate this

FIG 3 Generation of MHV68 G50DblKo and G50DbiKo.MR viruses. (A) Schematic diagram of alternatively initiated gene 50 transcripts. The locations of the known proximal and distal gene 50 promoters are shown. The two hatched areas depict the regions deleted within the mutant G50DbiKo virus: a 50-bp deletion extending from bp 65772 to 65822 in the distal promoter region and a 70-bp deletion extending from bp 66412 to 66482 in the proximal promoter region. There are two HindIII sites in the WT genome located at bp 64898 and 67541; the G50DbiKo virus has two additional HindIII sites introduced within the deletions, located at bp 65797 and 66447. The splicing of E1 to E2 driven by the proximal promoter and the splicing of E0 to E1 to E2 driven by the distal promoter are shown. (B) HindIII restriction endonuclease digests of G50DbiKo, G50PpKo, G50DbiKo.MR, G50PpKo.MR, G50galK, and WT-YFP BAC. The diagnostic restriction fragments are depicted (●). (C) Southern blot of the HindIII digest shown in panel B using a probe specific for the Orf50 region. Three unique digestion fragments are shown for the G50DbiKo virus, the WT and MR rescue viruses are shown to be the same, and the galK parent fails to hybridize the Orf50 probe due to the Orf50 region replacement with the G50PpKo cassette.
phenomenon, multistep growth curves were performed on both NIH 3T12 and Vero-Cre cells (Fig. 4). Consistent with the initial analyses, the G50DblKo mutant was able to grow in Vero-Cre cells, exhibiting only a mild replication defect (Fig. 4B), indicating that both the proximal and distal gene 50 promoters are dispensable for RTA expression in these cells. However, we failed to observe any growth of the G50DblKo mutant on NIH 3T12 fibroblasts (ca. a 4- to 5-log defect in viral titers between the marker rescue virus and the G50DblKo mutant at late times postinfection) (Fig. 4A).

Since a major difference between Vero cells and NIH 3T12 fibroblasts is that Vero cells lack the ability to generate type I interferons, we assessed whether a type I IFN response can block replication of the G50DblKo mutant virus. We infected mouse embryonic fibroblasts (MEFs) generated from C57BL/6 mice with the G50DblKo virus, and once again we failed to see efficient replication of the G50DblKo mutant at late times postinfection. To determine whether type I interferons were responsible for this large defect, we infected MEFs generated from 129S2/SvPas.IFN-α/βR-/- mice. Similar to the results obtained in Vero cells, the inability of the MEFs from mice lacking the IFN-α/β receptor to respond to a type I IFN response rescued the replication defect seen in the C57BL/6 MEFs (Fig. 5B). Notably, in the 129S2/SvPas.IFN-α/βR-/- MEFs, the G50DblKo virus replication was indistinguishable from that of wild-type virus (Fig. 5B). To directly examine the impact of type I IFNs on replication of the G50DblKo mutant, we compared virus replication in Vero cells in the absence and presence of IFN-α. Vero-Cre cells were pretreated with IFN-α and then treated every 24 h postinfection. Cells that were not treated with IFN-α, as seen before, showed normal growth and kinetics of the G50DblKo virus, similar to those of WT and G50DblKo.MR viruses (Fig. 5C). However, adding IFN-α severely inhibited replication of the G50DblKo mutant (Fig. 5D).

These analyses revealed an impact of type I interferons on in vitro replication of MHV68 (although it has previously been shown that acute viral titers in the lungs of IFN-α/βR−/− mice are significant higher than those in wild-type mice and that the absence of a type I IFN response renders mice highly susceptible to lethal MHV68 infection [26–28]). These analyses also reveal that, despite replication of the G50DblKo virus being attenuated in the presence of a type I IFN response, there appears to be little or no replication defect in comparison to wild-type virus when a type I interferon response is absent, due to either the lack of the IFN-α/βR or the absence of type I IFN expression. In addition, these analyses demonstrate that despite the deletion of the known gene 50 promoters, the G50DblKo mutant is replication competent under some experimental conditions, suggesting that there are alternative mechanisms for expression of the essential immediate early RTA.

Notably, upon higher-MOI infections, although there was a partial rescue of the G50DblKo growth defect, this mutant still exhibited a pronounced growth defect (Fig. 6A). Consistent with the observed growth defect, we observed a small-plaque phenotype (Fig. 6C), which was observed with 4 independently derived G50DblKo mutant BAC clones, making it unlikely that any of the observed phenotypes are the result of secondary mutations in the viral genome. However, when we examined the levels of RTA protein as a function of time postinfection, we observed a faster kinetics and higher levels of RTA at early times postinfection (Fig. 6B, 8-hour time point). This correlated with higher levels of the v-cyclin expression as well at 8 hours postinfection (Fig. 6B). This argues that the defect in virus replication is not directly attributable to failure to express RTA protein, although it does suggest that entry into the lytic cycle may be dysregulated and that this could lead to a defect in virion production.

Identification of three additional gene 50 transcripts driven by 2 promoters mapping upstream of the distal gene 50 promoter. We have previously shown that transcription of MHV68 gene 50 is driven by two distinct promoters: (i) the proximal promoter, encoding a short 288-bp exon, E1, which splices to the large 1,800-bp exon, E2 and (ii) the distal promoter, which encodes a short 181-bp exon, E0, which splices to E1, which in turn splices to E2 (6, 12, 16) (Fig. 1). We further showed that this organization of gene 50 transcription was conserved in both EBV and KSHV (16). The unexpected ability of the G50DblKo mutant to replicate under some experimental conditions indicated that there must exist alternative mechanisms for driving gene 50 transcription, since RTA is known to be absolutely required for virus replication (this has been shown for EBV, KSHV, and MHV68) (23, 29–32). To determine if this hypothesis was indeed correct, we performed 5’ RACE analysis of RNAs from Vero-Cre, RAW 264.7, and IFN-α/βR−/− MEFs infected with either wild-type MHV68 or the G50DblKo mutant. From this analysis, we were able to detect three previously unidentified gene 50 transcripts:...
which initiated from two distinct upstream transcription initiation sites (Fig. 7).

The three additional transcripts were identified in all three cell types examined and also were identified in both wild-type MHV68- and G50DblKo virus-infected cells. It is important to note that the 5’ RACE analyses conducted using the G50DblKo virus failed to detect the presence of any E1-E2 or E0-E1-E2 transcripts, further confirming that G50DblKo is indeed a true knock-

FIG 5 G50DblKo virus fails to replicate in vitro when IFN-α is present. (A) Multistep growth curve of C57BL/6 mouse embryonic fibroblasts (MEFs) infected with G50DblKo or WT-YFP virus at an MOI of 0.01. (B) Multistep growth curve of 129S2/SvPas.IFN-α/βR−/− mouse embryonic fibroblasts (IFN-α/βR−/− MEFs) infected with G50DblKo or WT-YFP virus at an MOI of 0.01. (C) Multistep growth curve of Vero-Cre cells infected with G50DblKo, G50DblKo.MR, or WT-YFP virus at an MOI of 0.1. (D) Multistep growth curve of Vero-Cre cells, treated with IFN-α (10,000U/ml) at the time of infection and every 24 h thereafter, infected with G50DblKo, G50DblKo.MR, or WT-YFP virus at an MOI of 0.1. All cells were collected at the times indicated, and experiments were repeated at least in triplicate.

FIG 6 Single-step growth analyses of the G50pDblKo mutant and analysis of the kinetics of RTA expression. (A) Single-step growth curve of G50pDblKo or WT-YFP virus in NIH 3T12 fibroblasts infected at an MOI of 10. (B) Western blot staining for RTA, v-cyclin, and β-actin expression from the same cells used in the single-step growth curve shown in panel A. (C) Representative sample of the small-plaque phenotype exhibited under all experimental conditions when using different G50pDblKo clones.

The three additional transcripts were identified in all three cell types examined and also were identified in both wild-type MHV68- and G50DbKo virus-infected cells. It is important to note that the 5’ RACE analyses conducted using the G50DblKo virus failed to detect the presence of any E1-E2 or E0-E1-E2 transcripts, further confirming that G50DblKo is indeed a true knock-
out of the proximal and distal gene 50 promoters. The first new exon, which we have termed N3, is a 330-bp extension of the previously characterized E0 exon. This new N3 exon is 511 bp long and maps to coordinates bp 65579 to 66090 in the MHV68 genome. The 3′ end of this exon is identical to the 3′ end of the E0 exon. Like E0, this newly identified N3 exon splices to the E1 exon, leading to removal of a 419-bp intron, which in turn splices to E2. Green arrows denote short ATG-initiated open reading frames that lie upstream of the RTA-coding sequences, which are indicated in blue. The locations of the major open reading frames antisense to gene 50 are also shown. Red arrows denote primers used in the 5′ RACE analyses. The positions of the primers used were as follows: E2-1, bp 68095 to 68066; E2-2, bp 68051 to 68027; E1, bp 66530 to 66509; and E0, bp 65930 to 65909.

Neither the N3 promoter nor the N4/N5 promoter exhibits sensitivity to IFN-α, but RTA levels from the G50DbkJKo mutant are diminished in the presence of a type I IFN response at low MOI. The identification of alternative gene 50 transcripts provides a clear mechanism by which the G50DbkJKo virus is apparently able to generate sufficient levels of RTA to drive virus replication, at least in the absence of a type I IFN response. However, it does not address the issue of why replication of the G50DbkJKo mutant is suppressed by type I IFNs. To begin to address this issue, we cloned 1,000-bp fragments immediately upstream of the 5′ ends of the N3 and N4/N5 transcripts into the pGL4.10 luciferase reporter vector (Promega Biotech) and transfected the resulting reporter constructs into Vero-Cre cells. While the N3 promoter resulted in expression 4-fold over that with empty vector, the N4/N5 promoter resulted in slightly higher levels of luciferase expression (13-fold over empty vector) (Fig. 8). These data demonstrate that the region immediately upstream of the newly identified gene 50 transcripts exhibits modest promoter activity.
To determine if the type I IFN-sensitive replication of the G50DblKo mutant virus reflects type I IFN-mediated suppression of gene 50 transcription from the G50DblKo mutant, we examined N3 and N4/N5 promoter activity in the presence of IFN-α treatment (Fig. 8). Since Vero cells fail to produce IFN-α but retain the ability to respond to exogenously added IFN-α (Fig. 5D), IFN-α was added to the transfected Vero cells and promoter activity assessed (Fig. 8). Similar luciferase assays of previously identified Orf50 transfected promoters have shown them to be sensitive to IFN-γ (33). However, our analysis showed no evidence of IFN-α suppression of reporter gene activity, suggesting that IFN-α inhibition of G50DblKo replication acts downstream of gene 50 transcription. This is consistent with the absence of any consensus IFN-stimulated response elements (ISREs) in the region upstream of the N3 and N4/N5 transcription initiation sites. Since it appeared that the newly identified gene 50 promoters are not sensitive to IFN-α, we examined the levels of RTA protein expression in wild-type MHV68- and G50DblKo mutant-infected cells. To assess RTA levels following infection, immunoblots were probed at several time points following low-MOI infection (Fig. 9). Consistent with the observed replication defect of the G50DblKo mutant virus in either NIH 3T12 fibroblasts or C57BL/6 MEFs, RTA levels were lower at all time points assessed (Fig. 9A and B). However, equivalent levels of RTA were detected in 129S2/SvPas. IFN-α/β−/− MEFs infected with either wild-type MHV68 or the G50DblKo mutant virus. It is also notable that RTA was readily detectable by 24 h postinfection of either C57BL/6 MEFs or 129S2/SvPas. IFN-α/β−/− MEFs but not NIH 3T12 fibroblasts (compare Fig. 9B and C with A). We have previously noted that MEFs are more sensitive to MHV68 infection as determined by a limiting-dilution CPE analysis which can detect between 0.1 and 0.2 PFU of virus with titers determined on NIH 3T12 fibroblasts (34), and this likely accounts for the earlier detection of RTA expression (i.e., effectively a higher-MOI infection).

When looking at RTA levels from growth curves following high-MOI infection, in which there is a partial rescue of the G50DblKo growth defect (Fig. 6A), the early kinetics and expression of RTA appear to be at similar or slightly higher levels than in WT infection (Fig. 6B). RTA was detectable at significant levels at 8 h postinfection in the G50DblKo virus-infected fibroblasts, while RTA was detectable at 12 h postinfection in WT virus-infected fibroblasts. However, the levels of RTA begin to wane by 24 h postinfection with the G50DblKo mutant, while WT RTA continues to increase. This may help explain the partial rescue of the growth phenotype at high MOI. Notably, the induction of v-cyclin expression parallels that of RTA expression for both the WT and G50DblKo infections. These results demonstrate that despite an increased sensitivity to type 1 interferons, as well as a partial growth defect at high MOI, the G50DblKo virus is able to generate functional RTA capable of driving transcription as well as launching expression of downstream viral targets such as v-cyclin.

The G50DblKo mutant establishes latency in the spleen and in PECs but is severely impaired for virus reactivation. To assess infection in mice with the G50DblKo mutant, we initially infected C57BL/6 mice intranasally with 1,000 PFU of either the G50DblKo virus, WT MHV68, or the G50DblKo.MR virus. We then assessed viral latency at day 18 postinfection, the peak of latency in the spleen. To assess latency in PECs, mice were infected with the G50DblKo virus, WT MHV68, or the G50DblKo.MR virus. We then assessed viral latency in PECs at day 18 postinfection.
latency in the spleen, and determined both the frequency of splenocytes harboring the viral genome and the frequency of splenocytes able to reactivate from latency. Splenocyte reactivation was determined by the previously described limiting-dilution CPE assay (20) modified by plating splenocytes on IFN-α/BR−/− MEF monolayers to ensure the ability to detect any reactivated G50DblKo mutant virus. The reactivation analyses revealed the nearly complete absence of detectable reactivation of the G50DblKo virus from splenocytes (Fig. 10A). In contrast, splenocytes harvested from wild-type virus-infected animals reactivated at a frequency of 1 in 7,035 cells, while the frequency of reactivation from the G50DblKo.MR virus was 1 in 9,549 cells (Fig. 10A and Table 1). No preformed infectious virus was detected in the harvested splenocyte samples, as measured by mechanical disruption of the cells as previously described (20) (data not shown).

To determine if this failure to reactivate from splenocytes observed with the G50DblKo mutant virus was the result of a failure to establish latency, limiting-dilution PCR was performed to determine the frequency of splenocytes harboring viral genomes (20). We observed that the frequency of splenocytes harboring latent virus was roughly equivalent for the wild-type virus and the G50DblKo.MR virus at 1 in 223 and 1 in 305 cells, respectively, while the G50DblKo mutant virus was present in splenocytes at a frequency of ca. 1 in 1,941 cells (Fig. 10B and Table 1). While the frequency of viral genome-positive splenocytes in the G50DblKo virus-infected animals was around 8.5-fold lower than that in the wild-type virus-infected animals, these analyses demonstrate that this mutant virus is able to get to the spleen and establish latency. Thus, the lack of detectable reactivation of the G50DblKo mutant reflects a significant defect in virus reactivation from B cells, the dominant latently infected cell population in the spleen (19, 35).

We extended these analyses to address whether the inability of the G50DblKo mutant virus to reactivate from splenocytes was dependent on the route of inoculation and to assess latency and reactivation from PECs. To do this we assessed virus reactivation from splenocytes and PECs following intraperitoneal (i.p.) inoculation. C57BL/6 mice were infected by intraperitoneal inoculation with 1,000 PFU of G50DblKo, wild-type, or G50DblKo.MR...
virus, and splenocytes and PECs were harvested at 18 days postinfection. We first examined the ability of the virus to reactivate from splenocytes, as described above. As observed following intranasal inoculation, the G50DblKo mutant exhibited a large defect in reactivation, although a low but significant level of virus reactivation was detectable (it was estimated by extrapolation that the G50DblKo mutant reactivates at a frequency of 1 in 422,863 splenocytes) (Table 1). In these analyses, wild-type virus reactivated at a frequency of 1 in 36,107 splenocytes, while the G50DblKo.MR virus reactivated at a frequency of 1 in 65,962 splenocytes (Table 1). Notably, the frequency of splenocytes reactivating virus at day 18 following intraperitoneal inoculation was 5- to 7-fold lower than that observed at the same time point following intranasal inoculation. This likely reflects faster kinetics of establishment and contraction of splenic latency following intraperitoneal inoculation. This effect, coupled with the observed low-level reactivation of the G50DblKo mutant, provides evidence that the route of inoculation does have an impact on reactivation of this mutant virus, which could be linked to better establishment of B cell latency (see discussion below). We then assessed whether the observed reactivation defects correlated with a defect in the establishment of latency. Notably, the 8.5-fold defect in establishment of latency in splenocytes observed following intranasal inoculation was largely rescued following intraperitoneal inoculation (Table 1). The frequency of viral genome-positive cells in the splenocytes following intraperitoneal inoculation was 1 in 388 cells for wild-type MHV68, 1 in 1,047 cells for the G50DblKo.MR virus, and 1 in 627 cells for the G50DblKo mutant (Table 1).

While nearly all virus reactivation from splenocytes arises from latently infected B cells (21, 36), macrophages represent the major latently infected cell type in PECs. Thus, to address whether the observed defect in G50DblKo reactivation from splenocytes reflects a B cell-specific defect, we determined the frequency of PECs reactivating virus. In contrast to the previous observation that the G50pKo virus retained the ability to reactivate from PECs (16), G50DblKo exhibited no detectable reactivation from PECs (Fig. 10C and Table 1). As expected, both wild-type MHV68 and the G50DblKo.MR virus reactivated from PECs, at frequencies of 1 in 17,782 cells and 1 in 14,417 cells, respectively (Fig. 10C and Table 1). These results indicate that despite the ability to drive viral replication, the absence of both the proximal and distal gene 50 promoters results in a substantial impairment in the ability of MHV68 to reactivate from infected cells in vivo. Despite rescue of establishment of latency in splenocytes following intraperitoneal inoculation, a ca. 6-fold defect in the establishment of latency in PECs was observed (the frequency of viral genome-positive PECs in wild-type-infected animals was 1 in 401 cells, in G50DblKo.MR-infected animals it was 1 in 562 cells, and in G50DblKo-infected animals it was ca. 1 in 2,137 cells) (Fig. 10D and Table 1). Despite the modest impairment of the G50DblKo mutant in the establishment of latency in PECs, it is clear that this mutant is significantly impaired in reactivation from latency from both splenic B cells and peritoneal macrophages.

**The G50DblKo phenotype in vivo is partially rescued in mice lacking the IFN-α/β receptor.** Since we have shown that the G50DblKo mutant virus retains the ability to grow with normal kinetics and to high titer in cells that lack a type 1 IFN response (Fig. 4B and 5B), we assessed whether the absence of a type 1 IFN response in vivo would rescue the G50DblKo replication and reactivation defects. Thus, we infected 129S2/SvPas.IFN-α/β−/− mice with 1,000 PFU of either the G50DblKo mutant or wild-type MHV68 via intranasal inoculation. It has previously been shown that MHV68 infection of mice lacking the IFN-α/β receptor results in the majority of mice succumbing during the acute phase of infection (26–28, 37). Surprisingly, while the G50DblKo mutant replicated to high titers in the lungs of IFN-α/β−/− mice (Fig. 11C), all infected mice survived (Fig. 11A). However, as expected, only 3 of 19 mice infected with 1,000 PFU wild-type MHV68 WT virus survived past 2 weeks postinfection (Fig. 11A). Parallel analyses in C57BL/6 mice confirmed the severe replication defect observed with the G50DblKo mutant (virus replication in the lungs was below the limit of detection in all infected mice). Notably, acute replication of the G50DblKo mutant in the lungs of IFN-α/β−/− mice with the G50DblKo mutant, we extended these studies using higher inoculating doses. We did not observe any lethality, even when mice were infected with a ca. 400-fold-higher dose of the G50DblKo mutant (5 of 5 mice infected survived for greater than 4 weeks postinfection) (Fig. 11D). Thus, while acute virus replication of the G50DblKo mutant in the lungs following intranasal inoculation was largely rescued by loss of a type 1 IFN response, MHV68-associated lethality was not observed, indicating a requirement for the gene 50 proximal and/or distal promoter for RTA expression in some anatomical site during the acute phase of virus infection.

**TABLE 1** Summary of virus latency and reactivation

<table>
<thead>
<tr>
<th>Mouse</th>
<th>Route</th>
<th>Day</th>
<th>Virus</th>
<th>Splenocytes</th>
<th>PECs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reactivation</td>
<td>Latency</td>
<td>Reactivation</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>i.n.</td>
<td>18</td>
<td>WT</td>
<td>1 in 7,035</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MR</td>
<td>1 in 9,549</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DblKo</td>
<td>Undetectable</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>i.p.</td>
<td></td>
<td>WT</td>
<td>1 in 36,107</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MR</td>
<td>1 in 65,962</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DblKo</td>
<td>1 in 422,863</td>
<td>ND</td>
</tr>
<tr>
<td>IFNαBR−/−</td>
<td>i.n.</td>
<td>28</td>
<td>WT a</td>
<td>1 in 77,624</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DblKo</td>
<td>1 in 52,420</td>
<td>ND</td>
</tr>
</tbody>
</table>

a ND, not determined.

Latency and reactivation were determined by pooling splenocytes from the 3 IFNαBR−/− mice that survived wild-type MHV68 infection.
Having shown that the severe defect in acute replication of the G50DblKo mutant observed in C57BL/6 mice was largely rescued in mice lacking the ability to respond to type I IFNs, we assessed establishment of latency and virus reactivation in IFN-\(\alpha/-\) mice. Spleens were harvested at day 28 from IFN-\(\alpha/-\) mice intranasally infected with 1,000 PFU of either wild-type or G50DblKo virus. It is important to note that the latency and reactivation analyses for wild-type virus-infected IFN-\(\alpha/-\) mice were carried out using the subset of infected animals that survived acute virus replication (Fig. 10A). Like the rescue of acute virus replication in the lungs, the frequency of viral genome-positive splenocytes went from a ca. 8-fold defect in i.n. infected C57BL/6 mice (Fig. 12B) to an almost identical frequency of virus-infected splenocytes (1 in 131 cells for wild-type MHV68 and 1 in 133 for the G50DblKo mutant) (Fig. 12A and Table 1). More importantly, the defect in virus reactivation observed in C57BL/6 mice was completely rescued in IFN-\(\alpha/-\) mice (1 in 77,624 splenocytes in WT-infected mice compared to 1 in 52,420 splenocytes in G50DblKo virus-infected mice) (Fig. 12B and Table 1). The latter result argues in favor of a model in which the sole defect in G50DblKo virus reactivation from C57BL/6 splenocytes is the inability to overcome type I IFN suppression of virus replication.

One possible explanation for the ability of the G50DblKo virus to replicate in the absence of type I interferons would be an increased expression of E1-E2 transcripts. This would make the G50DblKo virus not a true double promoter knockout virus, as E1-E2 transcripts would be responsible for the ability of the virus to replicate. However, this does not appear to be the case because (i) as shown in Fig. 6, RTA expression from the G50DblKo in...
normal fibroblasts is not impaired, and (ii) analysis of 5' RACE products generated from Vero cells, as well as IFN-α/βR−/− MEFs, using the G50DbKo virus failed to detect any proximal promoter (E1-E2)- or distal promoter (E0-E1-E2)-initiated transcripts. However, to more directly assess potential residual proximal promoter activity in the absence of a type I IFN response, we cloned both the proximal promoter and the proximal promoter deletion mutant into the pGL4.10Luc reporter plasmid. These reporter constructs were transfected into Vero cells, in the presence and absence of IFN-α treatment. Importantly, the proximal promoter does not appear to be sensitive to the presence of IFN-α (Fig. 13), which is consistent with the results shown in Fig. 5D where pretreatment with IFN-α has no effect on WT MHV68 growth. Furthermore, the proximal promoter deletion mutant exhibited significant lower promoter activity, in both the presence and absence of added IFN-α. Thus, taken together, these results argue against proximal promoter-driven RTA expression accounting for the rescue of G50DbKo virus replication in the absence of type I IFN.

**DISCUSSION**

Here we demonstrate that MHV68 gene 50 transcription is more complex than previously reported (6, 12, 16). Based on the current analyses, MHV68 RTA expression can be driven from four distinct promoters, and these promoters drive expression of 5 different spliced gene 50 transcripts. The identification of multiple promoters driving expression of a single gene is not a novel concept; there are many human and viral genes whose expression has been shown to be regulated by multiple promoters (38–42). For example, EBV has been shown to use differential splicing and from 2 distinct promoters in the generation of the transcripts encoding the six EBNA gene products (43–47). The use of multiple promoters is often the result of a complex life cycle and/or, particularly in the case of viruses, the infection of multiple cell types. We have shown that alternatively initiated gene 50 transcripts are conserved in MHV68-, KSHV-, and EBV-infected cells, having previously reported the detection of both proximal and distal promoter-initiated gene 50 transcripts (16). In addition, it has been previously shown by others that HVS RTA expression is driven from distinctly initiated transcripts expressed at different times in the viral replication cycle (48). Here we identify 2 additional gene 50 transcription initiation sites; gene 50 transcripts arising from these promoters could be detected in MHV68 infection of a macrophage cell line (RAW 264.7), a nonhuman primate epithelial cell line (Vero), and IFN-α/βR−/− mouse embryonic fibroblasts, indicating that these promoters appear to be widely active during virus replication and not restricted to a particular cell type. However, we have not carried out a detailed analysis of the abundance of specific gene 50 transcript species as a function of cell type or time postinfection, and it is certainly possible that their activities in vivo are more restricted. Thus, the current analyses do not rule out the possibility that the identified gene 50 promoters behave differently depending on cell type infected or address the role that each promoter plays in different cell types during the course of infection.

The utility of MHV68 infection of mice is that it provides a tractable small animal model to identify basic aspects of gammaherpesvirus pathogenesis that may be relevant to the human viruses EBV and KSV. Thus, we have begun to explore whether the complex gene 50 transcription observed during MHV68 replication is conserved in the human viruses. Notably, our preliminary characterization of gene 50 transcription during KSHV reactivation from latently infected B cells has identified multiple distinct gene 50 transcription initiation sites, as well as alternative splicing that is very similar to that observed in MHV68-infected cells (data not shown). Further analyses are necessary to fully characterize these novel gene 50 transcripts expressed during KSHV reactivation from B cells, as well as to characterize BRLF1 transcription during EBV infection.

The data presented here are among a limited number of studies (49) showing that type I interferons play an important role in suppressing MHV68 replication in tissue culture. This is strikingly different from the case for WT MHV68, where in vitro growth is not affected by the presence of type I interferons. However, it is important to emphasize that in vivo type I interferons play a critical role in controlling acute MHV68 replication, as mice lacking the IFN-α/β receptor are highly susceptible to lethal MHV68 infection (27, 28). In addition, it has previously been shown that type I interferons play a role in controlling viral reactivation from latency (27, 50).

The levels of RTA protein were greatly reduced in G50DbKo-infected cells in the presence of a type I IFN response (Fig. 9A and B), and abrogating the ability to respond to type I IFNs by disrupting IFN-α/βR rescued wild-type levels of RTA expression from the G50DbKo mutant virus (Fig. 9C). Since RTA is the first immediate early gene expressed during gammaherpesvirus infection, it directly and indirectly begins the lytic replication cascade by turning on a variety of downstream genes (51–57). Many of these downstream genes are responsible for an anti-type I interferon response, such as Orf45, M2, and Orf54 (58–63). Importantly, the ability of MHV68 to overcome the type I IFN response appears to be not only essential but also immediate. Growth curves where...
IFN-α was added prior to infection and during infection (Fig. 5D) demonstrate that the virus is able to overcome a type I IFN-induced antiviral cell environment; wild-type MHV68, even at a low MOI, is unaffected by IFN-α treatment. We hypothesize, then, that this may involve three distinct mechanisms. First, the virion contains a viral protein(s) able to suppress the type I IFN response. MHV68 proteins associated with the virion have been identified, and this includes the Orf45-encoded protein, which has already been implicated in regulating the type I IFN response (64). Second, this may involve the Orf45-encoded protein, which has already been implicated in regulating the type I IFN response (64). Second, RTA may itself be involved in mediating an anti-type I IFN response, but this would likely require that sufficient levels of RTA be expressed in an appropriate time frame postinfection to be effective. Third, RTA expression and function may be insensitive to type I interferon effects and thus able to initiate downstream gene signaling despite the presence of an antiviral cellular state. Future studies will need to address these possibilities.

It is notable that replication of G50DblKo is partially rescued in high-MOI infection. However, replication following high-MOI infection is still severely impaired (as shown in Fig. 6, titers never rise significantly above the input levels). Furthermore, this likely reflects the difference between a single cycle of replication versus the multiple rounds of replication required followed low-MOI infection. Indeed, following high-MOI infection, initial RTA levels following infection with the G50DblKo virus are higher than those in WT virus-infected fibroblasts, but these levels decrease over time (Fig. 6B, hours 16, 20, and 24). This indicates that RTA expression is dysregulated in G50DblKo infected cells and this likely impacts the tightly regulated lytic cascade ultimately leading to diminished virus production and the observed small plaque phenotype (Fig. 6C).

Overall these studies further reveal the complex nature of gammaherpesviruses replication. The identification of 3 additional Orf50 transcripts was surprising but likely illustrates how the virus has evolved to carefully control expression of the essential lytic switch gene. Though beyond the scope of this study, future work will investigate the function of these alternative gene 50 promoters and transcripts, as well as their presence/absence in other gammaherpesviruses. It is clear that in the absence of type 1 interferons, the newly identified gene 50 transcripts are able to drive viral replication nearly as efficiently as wild-type MHV68. This suggests that these promoters may play a cell type-specific and/or time-dependent role in the viral life cycle. Indeed, independent studies have recently revealed that the N4/N5 promoter is responsive to interleukin-4 (IL-4) treatment in macrophages, which has been shown to trigger MHV68 reactivation from latent infected macrophages (T. A. Reese et al., unpublished data). Another possibility is that upstream-initiated gene 50 transcription may, under some conditions, serve to suppress RTA expression by interfering with transcription from the more proximal gene 50 promoters. Transcriptional interference has been shown before for some EBV transcripts (44, 65–67). In addition, the role of the short ATG-initiated open reading frames in the 5’ untranslated regions of upstream-initiated gene 50 transcripts remains to be investigated.

In summary, the analysis of the G50DblKo mutant extends our understanding of RTA expression and has revealed a hitherto-unappreciated complexity of gene 50 transcription. It is notable that until the analysis of the G50DblKo mutant, little or no impact of type I interferons on wild-type MHV68 replication was observed. This was in stark contrast to the analysis of MHV68 replication during the acute stages of infection in IFN-α/βR−/− mice, where substantially higher levels of virus replication are observed in the lungs of type I interferon-unresponsive mice than in those of wild-type mice following i.n. virus inoculation (e.g., see Fig. 11) (28). Based on the observations with G50DblKo mutant replication in vitro, it is perhaps reasonable to speculate that during acute virus replication there may be a role for type I IFN-sensitive gene 50 transcription. Future studies will address whether any of the newly identified gene 50 transcripts play such a role during acute virus replication in vivo.

ACKNOWLEDGMENTS

We thank members of the Speck lab for helpful comments. This research was supported by NIH R01 grant CA52004 to S.H.S. S.H.S. was also supported by NIH R01 grants AI073830, CA095318, and AI058057.

REFERENCES


